AUSTIN, Texas–(BUSINESS WIRE)–Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled “Characterising the efficacy of multi-node PI3K/AKT/mTOR pathway inhibition with serabelisib and sapanisertib (PIKTOR) in combination with SERDs and a CDK4/6